(VIANEWS) – Ambac Financial Group (AMBC), Freeport (FCX), Cadence Design Systems (CDNS) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Ambac Financial Group (AMBC)
34.1% sales growth and 4.2% return on equity
Ambac Financial Group, Inc., a financial services holding company, provides financial guarantees in the United States, the United Kingdom, Italy, Austria, Australia, France, and Internationally. It offers financial guarantee insurance policies; and credit derivative contracts and interest rate derivative transactions. The company was incorporated in 1991 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Ambac Financial Group has a trailing twelve months EPS of $1.34.
PE Ratio
Ambac Financial Group has a trailing twelve months price to earnings ratio of 13.42. Meaning, the purchaser of the share is investing $13.42 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.2%.
Sales Growth
Ambac Financial Group’s sales growth is 18.2% for the current quarter and 34.1% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 68.3%, now sitting on 310M for the twelve trailing months.
2. Freeport (FCX)
25.4% sales growth and 14.38% return on equity
Freeport-McMoRan Inc. engages in the mining of mineral properties in North America, South America, and Indonesia. It primarily explores for copper, gold, molybdenum, silver, and other metals. The company's assets include the Grasberg minerals district in Indonesia; Morenci, Bagdad, Safford, Sierrita, and Miami in Arizona; Chino and Tyrone in New Mexico; and Henderson and Climax in Colorado, North America, as well as Cerro Verde in Peru and El Abra in Chile. The company was formerly known as Freeport-McMoRan Copper & Gold Inc. and changed its name to Freeport-McMoRan Inc. in July 2014. Freeport-McMoRan Inc. was incorporated in 1987 and is headquartered in Phoenix, Arizona.
Earnings Per Share
As for profitability, Freeport has a trailing twelve months EPS of $1.28.
PE Ratio
Freeport has a trailing twelve months price to earnings ratio of 38.65. Meaning, the purchaser of the share is investing $38.65 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.38%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is 8.6% and a drop 2.6% for the next.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Apr 12, 2024, the estimated forward annual dividend rate is 0.6 and the estimated forward annual dividend yield is 1.11%.
Moving Average
Freeport’s value is higher than its 50-day moving average of $48.47 and way higher than its 200-day moving average of $40.90.
Yearly Top and Bottom Value
Freeport’s stock is valued at $49.47 at 20:22 EST, below its 52-week high of $54.35 and way higher than its 52-week low of $32.83.
3. Cadence Design Systems (CDNS)
16.7% sales growth and 32.17% return on equity
Cadence Design Systems, Inc. provides software, hardware, services, and reusable integrated circuit (IC) design blocks worldwide. The company offers functional verification services, including emulation and prototyping hardware. Its functional verification offering consists of JasperGold, a formal verification platform; Xcelium, a parallel logic simulation platform; Palladium, an enterprise emulation platform; and Protium, a prototyping platform for chip verification. The company also provides digital IC design and sign off products, including Genus synthesis and Joules RTL power solutions, as well as Modus DFT software solution to reduce systems-on-chip design-for-test time; physical implementation tools, such as place and route, optimization, and multiple patterning preparation; and Innovus implementation system, a physical implementation system. In addition, it offers custom IC design and simulation products to create schematic and physical representations of circuits down to the transistor level for analog, mixed-signal, custom digital, memory, and radio frequency designs; and system design and analysis products to develop printed circuit boards and IC packages, as well as to analyze electromagnetic, electro-thermal, and other multi-physics effects. Further, the company provides intellectual property (IP) products comprising pre-verified and customizable functional blocks to integrate into customer's ICs; and verification IP with memory models to emulate and model the expected behavior and interaction of standard industry system interface protocols. Additionally, it offers services related to methodology, education, and hosted design solutions, as well as technical support and maintenance services. The company serves consumer, hyperscale computing, 5G communications, mobile, automotive, aerospace and defense, industrial, and life science industries. Cadence Design Systems, Inc. was incorporated in 1987 and is headquartered in San Jose, California.
Earnings Per Share
As for profitability, Cadence Design Systems has a trailing twelve months EPS of $3.81.
PE Ratio
Cadence Design Systems has a trailing twelve months price to earnings ratio of 80.28. Meaning, the purchaser of the share is investing $80.28 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 32.17%.
Moving Average
Cadence Design Systems’s worth is above its 50-day moving average of $297.46 and way higher than its 200-day moving average of $270.16.
4. Agree Realty Corporation (ADC)
13% sales growth and 3.48% return on equity
Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of June 30, 2020, the Company owned and operated a portfolio of 936 properties, located in 46 states and containing approximately 18.4 million square feet of gross leasable area. The common stock of Agree Realty Corporation is listed on the New York Stock Exchange under the symbol "ADC".
Earnings Per Share
As for profitability, Agree Realty Corporation has a trailing twelve months EPS of $1.69.
PE Ratio
Agree Realty Corporation has a trailing twelve months price to earnings ratio of 34.53. Meaning, the purchaser of the share is investing $34.53 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.48%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Apr 29, 2024, the estimated forward annual dividend rate is 3 and the estimated forward annual dividend yield is 5.07%.
5. Option Care Health (OPCH)
10% sales growth and 19.62% return on equity
Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as multiple sclerosis, duchenne muscular dystrophy, and others; infusion therapies for bleeding disorders; therapies that women need to survive and thrive through high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. Option Care Health, Inc. is headquartered in Bannockburn, Illinois.
Earnings Per Share
As for profitability, Option Care Health has a trailing twelve months EPS of $1.53.
PE Ratio
Option Care Health has a trailing twelve months price to earnings ratio of 19.62. Meaning, the purchaser of the share is investing $19.62 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.62%.
Sales Growth
Option Care Health’s sales growth is 9.5% for the current quarter and 10% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 12.8%, now sitting on 4.43B for the twelve trailing months.
Yearly Top and Bottom Value
Option Care Health’s stock is valued at $30.02 at 20:22 EST, way below its 52-week high of $35.74 and way above its 52-week low of $26.17.
6. Kamada Ltd. (KMDA)
5.3% sales growth and 5.91% return on equity
Kamada Ltd., together with its subsidiaries, provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. It has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. Kamada Ltd. was incorporated in 1990 and is headquartered in Rehovot, Israel.
Earnings Per Share
As for profitability, Kamada Ltd. has a trailing twelve months EPS of $0.23.
PE Ratio
Kamada Ltd. has a trailing twelve months price to earnings ratio of 23.57. Meaning, the purchaser of the share is investing $23.57 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.91%.
Volume
Today’s last reported volume for Kamada Ltd. is 18082 which is 16.63% below its average volume of 21690.
Yearly Top and Bottom Value
Kamada Ltd.’s stock is valued at $5.42 at 20:22 EST, way under its 52-week high of $6.53 and way above its 52-week low of $4.08.
Sales Growth
Kamada Ltd.’s sales growth is 4.6% for the current quarter and 5.3% for the next.
